Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients

Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity remain uncertain; consequently, we sought to compare Sac/Val vs. standard medical therapy, in terms of effects on...

Descripción completa

Detalles Bibliográficos
Autores principales: Campanile, Alfonso, Visco, Valeria, De Carlo, Stefania, Ferruzzi, Germano Junior, Mancusi, Costantino, Izzo, Carmine, Mongiello, Felice, Di Pietro, Paola, Virtuoso, Nicola, Ravera, Amelia, Bonadies, Domenico, Vecchione, Carmine, Ciccarelli, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220971/
https://www.ncbi.nlm.nih.gov/pubmed/37240819
http://dx.doi.org/10.3390/life13051174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220971/
https://www.ncbi.nlm.nih.gov/pubmed/37240819
http://dx.doi.org/10.3390/life13051174

Ejemplares similares